Introduction: Interferon regulatory factor 4 (IRF4) is a transcriptional factor with a key role in the modulation of inflammation and immune surveillance. The IRF4 gene is downregulated in Philadelphia-negative myeloproliferative neoplasms, and its expression is associated with prognosis and response to treatment. Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. Results: A relationship between the IRF4 expression and the disease burden was observed at various disease stages. A correlation analysis between the International Scale (IS) and IRF4 values confirmed this close association. A significant increase is detected after 3 months of TKI treatment. Patients achieving an early molecular response (EMR) had higher IRF4 values at both diagnosis and after 3 months of therapy as compared to those failing the EMR target. Patients achieving treatment-free remission did not show IRF4 fluctuations during monitoring, while a decreased IRF4 expression emerged at the time of molecular relapse. Conclusion: Our data seem to confirm the relevance of IRF4 in the pathogenesis of CML, suggesting a pivotal role at the disease onset and a predictive value during the CML course.

Keywords:
Chronic myeloid leukemia, IRF4, Molecular response, Tyrosine kinase inhibitors, Treatment-free remission
1.
Nam S, Lim JS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res. 2016 Nov;39(11):1548–55.
2.
Nam S, Kang K, Cha JS, Kim JW, Lee HG, Kim Y, et al. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. J Leukoc Biol. 2016 Dec;100(6):1273–84.
3.
Cumbo C, Tarantini F, Anelli L, Zagaria A, Redavid I, Minervini CF, et al. IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. Exp Hematol Oncol. 2021;10(1):58.
4.
Schmidt M, Hochhaus A, König-Merediz SA, Brendel C, Proba J, Hoppe GJ, et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol. 2000;18(19):3331–8.
5.
Yang Q, Xie H, Li X, Feng Y, Xie S, Qu J, et al. Interferon regulatory factor 4 regulates the development of Polymorphonuclear myeloid-derived suppressor cells through the transcription of c-Myc in cancer. Front Immunol. 2021;12:627072.
6.
Günthner R, Anders HJ. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm. 2013;2013:731023.
7.
Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG. Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms. Curr Hematol Malig Rep. 2019 Jun;14(3):145–53.
8.
Arthur D, Fisher C, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol. 2021 Jun 1;12:683401.
9.
Kapor S, Santibanez JF. Myeloid-derived suppressor cells and mesenchymal stem/stromal cells in myeloid malignancies. J Clin Med. 2021;10(13):2788.
10.
Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C, et al. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res. 2016 Apr;43:39–43.
11.
Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol. 2021;113(5):642–7.
12.
Raccuia SA, Di Rosa M, Brundo MV, Giallongo C, Parrinello N, La Cava P, et al. Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol. 2015;5:107.
13.
Albano F, Anelli L, Zagaria A, Archidiacono N, Liso V, Specchia G, et al. “Home-brew” FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;174(2):121–6.
14.
van Dongen J, Macintyre E, Gabert J, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 1999;13(12):1901–28.
15.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.
16.
Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999–1003.
17.
Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–60.
18.
Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33(7):1543–56.
19.
Hagman J. Critical functions of IRF4 in B and T lymphocytes. J Immunol. 2017;199(11):3715–6.
20.
Sun Y, Han X, Shang C, Wang Y, Xu B, Jiang S, et al. The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. Cell Death Dis. 2022 Jan 10;13(1):36.
21.
Longhitano L, Li Volti G, Giallongo C, Spampinato M, Barbagallo I, Di Rosa M, et al. The role of inflammation and inflammasome in myeloproliferative disease. J Clin Med. 2020 Jul;9(8):2334.
22.
Zhang Y, Zeng X, Zha X, Lai J, Tan G, Chen S, et al. Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients. Hematology. 2022;27(1):523–9.
23.
Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica. 2020;105(12):2730–7.
24.
Müller MC, Lauseker M, Hehlmann R, Hanf­stein B, Dietz C, Erben P, et al. Achievement of a MR5.0 within the randomized CML-study IV: feasibility, differences between treatment arms, and prognostic implications. Blood. 2013;122(21):4008.
25.
Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017;12(2):79–84.
26.
Ureshino H, Shindo T, Tanaka H, Saji H, Kimura S. HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Mol Cancer Ther. 2021 Jan;20(1):142–149.
© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.